Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy
Conclusion: Although hematological toxicities were severe, these results suggested that amrubicin in NSCLC patients beyond third-line therapy shows sufficient clinical benefit.Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology